| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
17,247 |
15,032 |
$420K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
17,295 |
15,084 |
$396K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
39,042 |
33,968 |
$232K |
| 80053 |
Comprehensive metabolic panel |
26,724 |
23,682 |
$195K |
| 80061 |
Lipid panel |
20,127 |
17,864 |
$182K |
| 84443 |
Thyroid stimulating hormone (TSH) |
13,743 |
12,103 |
$157K |
| 87480 |
|
11,498 |
9,846 |
$153K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
9,385 |
8,196 |
$152K |
| 87660 |
|
11,415 |
9,812 |
$152K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
8,273 |
7,166 |
$149K |
| 87510 |
|
11,433 |
9,778 |
$138K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
5,362 |
3,814 |
$130K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,609 |
1,401 |
$118K |
| 86780 |
|
11,262 |
9,774 |
$108K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,098 |
2,397 |
$96K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
14,538 |
12,771 |
$90K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12,778 |
11,081 |
$73K |
| 80050 |
General health panel |
2,684 |
2,358 |
$70K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,772 |
1,268 |
$66K |
| 87653 |
|
2,775 |
2,423 |
$65K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
2,432 |
2,210 |
$59K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
2,808 |
2,332 |
$51K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
7,831 |
6,801 |
$50K |
| 80074 |
|
1,816 |
1,539 |
$41K |
| 82607 |
|
4,101 |
3,622 |
$41K |
| 87077 |
|
5,803 |
4,936 |
$37K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
784 |
729 |
$37K |
| 86696 |
|
2,781 |
2,494 |
$36K |
| 86803 |
|
3,786 |
3,215 |
$36K |
| 83655 |
|
4,315 |
3,818 |
$34K |
| 86762 |
|
3,178 |
2,744 |
$34K |
| 84439 |
|
5,788 |
5,057 |
$34K |
| 87186 |
|
5,053 |
4,263 |
$33K |
| 87340 |
|
4,289 |
3,769 |
$33K |
| 84702 |
|
3,505 |
2,614 |
$30K |
| 36415 |
Collection of venous blood by venipuncture |
16,825 |
12,880 |
$29K |
| 86695 |
|
2,794 |
2,497 |
$28K |
| 82746 |
|
2,565 |
2,220 |
$23K |
| 86850 |
|
3,525 |
3,141 |
$21K |
| 86694 |
|
1,902 |
1,589 |
$20K |
| 82043 |
|
4,628 |
4,179 |
$18K |
| 82728 |
|
2,073 |
1,841 |
$18K |
| 82570 |
|
5,090 |
4,471 |
$18K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,145 |
698 |
$17K |
| 83550 |
|
2,391 |
2,161 |
$15K |
| 87428 |
|
356 |
315 |
$15K |
| 80081 |
|
235 |
213 |
$13K |
| 81001 |
|
5,586 |
4,843 |
$13K |
| 87070 |
|
1,945 |
1,744 |
$13K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
314 |
210 |
$13K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
226 |
197 |
$12K |
| 83540 |
|
2,628 |
2,377 |
$12K |
| 82950 |
|
2,893 |
2,497 |
$10K |
| 87081 |
|
1,819 |
1,664 |
$10K |
| 86703 |
|
948 |
860 |
$10K |
| 85660 |
|
2,423 |
2,116 |
$9K |
| 83880 |
|
378 |
330 |
$8K |
| 80076 |
|
1,341 |
1,196 |
$8K |
| 87088 |
|
1,188 |
985 |
$7K |
| 86038 |
|
825 |
705 |
$7K |
| 84703 |
|
1,280 |
1,060 |
$7K |
| 86900 |
|
3,273 |
2,925 |
$6K |
| 86901 |
|
3,219 |
2,874 |
$6K |
| 83001 |
|
356 |
310 |
$5K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
432 |
390 |
$5K |
| 86140 |
|
1,379 |
1,128 |
$5K |
| 81003 |
|
1,976 |
1,730 |
$4K |
| 87210 |
|
1,231 |
980 |
$4K |
| 80305 |
|
682 |
617 |
$4K |
| 85651 |
|
1,445 |
1,180 |
$4K |
| 84550 |
|
1,088 |
952 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
178 |
121 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
285 |
168 |
$3K |
| 83735 |
|
801 |
708 |
$3K |
| 84403 |
|
212 |
183 |
$3K |
| 86003 |
|
219 |
100 |
$3K |
| 82947 |
|
1,011 |
898 |
$3K |
| 86706 |
|
390 |
350 |
$3K |
| 87506 |
|
15 |
15 |
$3K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
532 |
450 |
$2K |
| 80164 |
|
233 |
201 |
$2K |
| 83690 |
|
479 |
427 |
$2K |
| 83002 |
|
152 |
130 |
$2K |
| 83970 |
|
55 |
49 |
$2K |
| 85610 |
|
632 |
430 |
$1K |
| 85018 |
|
723 |
632 |
$1K |
| 86787 |
|
133 |
126 |
$1K |
| 82248 |
|
275 |
249 |
$1K |
| 84144 |
|
76 |
65 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
86 |
85 |
$1K |
| 86592 |
|
345 |
292 |
$980.16 |
| 84146 |
|
69 |
59 |
$855.30 |
| 84153 |
|
61 |
56 |
$852.54 |
| 82150 |
|
196 |
166 |
$842.35 |
| 82677 |
|
54 |
48 |
$818.33 |
| 84156 |
|
357 |
293 |
$774.96 |
| 87807 |
|
79 |
69 |
$683.65 |
| 81025 |
|
123 |
106 |
$630.78 |
| 85014 |
|
301 |
277 |
$554.72 |
| 84481 |
|
43 |
41 |
$527.32 |
| 86336 |
|
54 |
48 |
$511.48 |
| 82105 |
|
41 |
38 |
$425.71 |
| 86431 |
|
99 |
94 |
$366.09 |
| 84436 |
|
87 |
81 |
$348.07 |
| 87529 |
|
13 |
12 |
$315.80 |
| 82785 |
|
72 |
52 |
$304.69 |
| 84478 |
|
87 |
77 |
$258.89 |
| 82550 |
|
66 |
55 |
$203.65 |
| 86430 |
|
45 |
39 |
$203.10 |
| 85730 |
|
53 |
50 |
$195.06 |
| 80185 |
|
16 |
13 |
$188.94 |
| 86376 |
|
24 |
17 |
$176.20 |
| 82784 |
|
19 |
13 |
$166.39 |
| 84460 |
|
43 |
41 |
$152.66 |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
27 |
27 |
$80.93 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19 |
16 |
$64.73 |
| 85046 |
|
12 |
12 |
$63.33 |
| 82565 |
|
15 |
14 |
$52.10 |
| 80069 |
|
14 |
12 |
$27.15 |
| 93000 |
|
20 |
17 |
$26.34 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
13 |
13 |
$21.05 |
| 87390 |
|
13 |
13 |
$20.57 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
90 |
71 |
$5.68 |
| 71045 |
Radiologic examination, chest; single view |
63 |
47 |
$2.64 |
| 80373 |
|
14 |
13 |
$0.00 |
| 80346 |
|
14 |
13 |
$0.00 |
| 80365 |
|
13 |
12 |
$0.00 |
| 80348 |
|
14 |
13 |
$0.00 |
| 71046 |
Radiologic examination, chest; 2 views |
42 |
17 |
$0.00 |
| 80361 |
|
13 |
12 |
$0.00 |
| 80372 |
|
27 |
25 |
$0.00 |
| 80354 |
|
13 |
12 |
$0.00 |
| 80356 |
|
13 |
12 |
$0.00 |
| 3044F |
|
86 |
86 |
$0.00 |
| 80358 |
|
14 |
13 |
$0.00 |
| 80324 |
|
13 |
12 |
$0.00 |
| 80353 |
|
13 |
12 |
$0.00 |
| 81511 |
|
18 |
16 |
$0.00 |
| 80349 |
|
14 |
13 |
$0.00 |